1. Home
  2. VGAS vs NOTV Comparison

VGAS vs NOTV Comparison

Compare VGAS & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verde Clean Fuels Inc.

VGAS

Verde Clean Fuels Inc.

N/A

Current Price

$2.75

Market Cap

63.9M

Sector

Industrials

ML Signal

N/A

Logo Inotiv Inc.

NOTV

Inotiv Inc.

HOLD

Current Price

$0.80

Market Cap

29.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VGAS
NOTV
Founded
2007
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.9M
29.9M
IPO Year
N/A
1997

Fundamental Metrics

Financial Performance
Metric
VGAS
NOTV
Price
$2.75
$0.80
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
9.6K
1.6M
Earning Date
11-13-2025
12-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$513,024,000.00
Revenue This Year
N/A
$6.26
Revenue Next Year
N/A
$45.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
4.54
52 Week Low
$2.49
$0.66
52 Week High
$4.39
$6.48

Technical Indicators

Market Signals
Indicator
VGAS
NOTV
Relative Strength Index (RSI) 42.75 37.28
Support Level $2.49 $0.79
Resistance Level $2.79 $0.86
Average True Range (ATR) 0.19 0.07
MACD 0.01 0.01
Stochastic Oscillator 34.78 18.21

Price Performance

Historical Comparison
VGAS
NOTV

About VGAS Verde Clean Fuels Inc.

Verde Clean Fuels Inc is a renewable energy company specializing in the conversion of synthesis gas, or syngas, derived from diverse feedstocks, such as biomass, MSW, and mixed plastics, as well as natural gas (including synthetic natural gas) and other feedstocks, into liquid hydrocarbons that can be used as gasoline through a proprietary liquid fuels technology, the STG process.

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Share on Social Networks: